Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

Help your patients get started with Nurtec ODT
Ordering samples

For your patients with migraine, providing samples can be a great way to have them get started with their Nurtec ODT treatment. Follow the link below to order.
 


Please be aware that your eligibility to order Nurtec ODT samples on PfizerPro is determined by your
experience prescribing Nurtec ODT within the last 12 months.

Quarterly allocation

If you do not see Nurtec ODT on your sample list, come back later and try again. It may not have you on the list because it doesn’t have your history established or your quarterly allocation may have been exhausted—in both cases, the system will update.
 PP-NNT-USA-5221

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

Efficacy & Safety ProfileEfficacy & Safety ProfileAcutePivotal TrialLong-Term Safety StudyTriptan Unsuitable StudyPreventivePivotal TrialPivotal Open-Label Safety ExtensionPrior Inadequate Response StudyCHALLENGE-MIG StudyDosingAbout NurtecAbout NurtecMechanism of ActionPatient ProfilesAccess & SupportAccess &
SupportSearch for CoveragePrior AuthorizationPrescribingSavings & SupportResources
Prescribing InformationIndicationsPatient InformationPatient Website

For the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults1

 Acute Clinical DataLoading

Preventive Clinical Data

Loading

Preventive Clinical Data

Loading Rapid relief.
Powerful prevention. Nurtec ODT does both.1-3
For acute treatment at 2 hours, 21.2% of patients on Nurtec ODT (n=142/669) achieved migraine pain freedom vs 10.9% on placebo (n=74/682) (Δ10.3%*; P<0.001), and 35.1% achieved freedom from most bothersome symptom (MBS) vs 26.8% on placebo (Δ8.3%*; P=0.001) (coprimary endpoints). For preventive treatment, rimegepant 75 mg (n=348) reduced patients' monthly migraine days (MMDs) by 4.3 days vs 3.5 days for those on placebo (n=347) at weeks 9–12 compared with baseline observation period (Δ-0.8†; P=0.01).1-3
 Access & Support
Nurtec ODT has extensive coverage on both national and regional health plans.§
 Learn about coverage Loading Samples
Get samples for your appropriate patients. Request yours today.
 Order samples Loading Dosing
The only orally disintegrating tablet for acute and preventive treatment.1,5
 Explore dosing LoadingResources for you and your patients

Access resources, clinical data, treatment guidelines, and more, all in one place.

 Browse resources Loading Browse resources Loading Built to support individualized migraine care

Nurtec ODT is the only oral CGRP antagonist FDA-approved for both the acute and preventive treatment of migraine.1,5

The extensive clinical program includes 6 randomized trials in acute treatment and 5 randomized trials in prevention, with more than 10,700 patients evaluated¶# and 2 million∥ patients prescribed.2,4,6-18

 See the evidence LoadingNumber of patients evaluated reflects all treated participants in the study population, including rimegepant (n=6132) and comparator (n=4610) recipients.CGRP=calcitonin gene-related peptide; FDA=US Food and Drug Administration; LAAD=Longitudinal Access and Adjudication Data; MBS=most bothersome symptom; MMDs=monthly migraine days.References†Differences from placebo were calculated using the Cochran-Mantel-Haenszel method.2‡Analyzed using a generalized linear mixed-effects model with treatment group, preventive migraine medication use at randomization, study month, and month-by-treatment group interaction as fixed effects and participant as random effect.4§Per Managed Markets Insight & Technology, LLC, formulary data are current as of November 2025. The information provided is not a guarantee of coverage or payment (partial or full), and is subject to change without notice. Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Please confirm coverage with each patient’s plan. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.#The FDA-approved Prescribing Information for Nurtec ODT (rimegepant) only includes information from Study 303, 201, and 305, including the open-label extension phase. Data and dosing regimens included in the publications referenced here may be different from or are not included in the Nurtec ODT Prescribing Information. Data from ex-US studies may not be generalizable to US patients.∥Based on IQVIA LAAD data as of July 2026.References:Nurtec ODT Package insert. Pfizer Inc.Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745.Data on file. BHV3000-303. Clinical Study Report. Pfizer Inc.Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60.Blair HA. Rimegepant: a review in the acute treatment and preventive treatment of migraine. CNS Drugs. 2023;37(3):255-265. Published correction appears in CNS Drugs. 2023;37(7):661.Lipton RB, Thiry A, Morris BA, Croop R. Efficacy and safety of rimegepant 75 mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. J Pain Res. 2024;17:2431-2441.Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142-149.Yu S, Kim BK, Guo A, Kim MH, Zhang M, Wang Z, et al. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2023;22(6):476-484.Ikeda K, Matsumori Y, Kudo M, et al. Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: a dose-ranging, double-blind, randomized controlled trial. Headache. 2025;65(10):1811-1820.Croop R, Berman G, Kudrow D, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024;44(4):3331024241232944.Ashina M, McAllister P, Gaul C, Leyva-Rendon A, Ramirez LM, Nalpas C, et al. Rimegepant for acute treatment of migraine in triptan-unsuitable adults: a randomized, double-blind, placebo-controlled phase 4 trial. Cephalalgia. 2025;45(11):3331024251395298.Lipton RB, Abraham L, Urani A, et al. Consistency of response to rimegepant for the acute treatment of migraine among real-world users – findings from the prospective observational CONFIDENCE study. J Headache Pain. 2026;27(1):200. Lipton RB, Goadsby PJ, Pozo-Rosich P, et al. Effectiveness of rimegepant for the acute treatment of migraine among participants using different types of preventive therapy: analyses from CONFIDENCE. Neurol Ther. 2026Kudrow D, Croop RS, Thiry A, Lipton RB. A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache. 2026;66(2):407-416.Kitamura S, Matsumori Y, Yamamoto T, et al. Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-­blind, randomized controlled trial. Headache. 2025;65(8):1403-1412.Yu S, Fountaine RJ, Ma L, Han X, Zhong Q. Rimegepant for the preventive treatment of migraine: a phase 3, randomized, double-blind, placebo-controlled study in adults from China. Poster presented at: American Headache Society 68th Annual Scientific Meeting; June 4-7, 2026.Schwedt TJ, Myers Oakes TM, Martinez JM, et al. Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. Neurol Ther. 2024;13(1):85-105.Pozo-Rosich P, Gien Lopez JA, Lisewski P, et al. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications. Cephalalgia. 2025;45(11):1-13.

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-NNT-USA-5806
You are now leaving PfizerPro You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-NNT-USA-5221
INDICATIONSNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine
Please click here for full Prescribing Information.
Important Safety Information Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included anaphylaxis, dyspnea, and rash and can occur days after administration. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted. Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.If signs or symptoms of Raynaud’s phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%). Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp. Use in Specific Populations: Pregnancy: It is not known if Nurtec ODT can harm an unborn baby.

Lactation: The transfer of rimegepant into breast milk is low (<1%). Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.

IndicationsNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine
Please click here for full Prescribing Information.
Help your patients get started with Nurtec ODT
Ordering samples

For your patients with migraine, providing samples can be a great way to have them get started with their Nurtec ODT treatment. Follow the link below to order.
 


Please be aware that your eligibility to order Nurtec ODT samples on PfizerPro is determined by your
experience prescribing Nurtec ODT within the last 12 months.

Quarterly allocation

If you do not see Nurtec ODT on your sample list, come back later and try again. It may not have you on the list because it doesn’t have your history established or your quarterly allocation may have been exhausted—in both cases, the system will update.
 PP-NNT-USA-5221